05:31 , May 2, 2019 |  BC Extra  |  Company News

AstraZeneca adds oncolytic virus option through Transgene deal

AstraZeneca is taking another look at oncolytic viruses through an option deal with French biotech Transgene. On Thursday, the partners said AstraZeneca plc (LSE:AZN; NYSE:AZN) would receive an exclusive option to co-develop and commercialize five...
20:32 , Nov 30, 2018 |  BC Week In Review  |  Company News

Parker Institute, PsiOxus to test virus-based cancer immunotherapies

PsiOxus Therapeutics Ltd. (Abingdon, U.K.) partnered with the Parker Institute for Cancer Immunotherapy to conduct preclinical research of PsiOxus’ IV virus-based gene therapy to treat solid tumors. The partners will build and test viruses carrying...
18:52 , Jul 12, 2018 |  BC Innovations  |  Product R&D

All-in-one viruses

Having taken its lead oncolytic virus into the clinic, PsiOxus Therapeutics Ltd. is building an immuno-oncology platform that uses engineered versions of the vector to selectively target multiple genes at a time to tumor cells...
00:42 , Aug 12, 2017 |  BioCentury  |  Product Development

HBV test kitchen

Early results for HBV monotherapies are pointing the way toward combinations that could deliver a functional cure. What remains unknown is how many components, and which ones, will prove necessary to eliminate remnants of the...
07:00 , Apr 7, 2016 |  BC Innovations  |  Tools & Techniques

Sexy sequencing

Tim Harris, Venture Partner, SV Life Sciences  The days when PhDs were minted based on sequencing a few nucleotides at the end of a piece of nucleic acid are definitely gone. The countless hours spent...
07:00 , Oct 6, 2014 |  BioCentury  |  Emerging Company Profile

Nirmidas: Improving NIR-sightedness

Nirmidas Biotech Inc. 's pGOLD platform can amplify the signal output of near-infrared fluorescent dyes over a hundredfold, which improves their sensitivity for low-concentration analytes in ELISA or other assays that rely on fluorescent readouts....
01:55 , Dec 5, 2013 |  BC Extra  |  Top Story

Juno debuts with $120 million

Cancer immunotherapy play Juno Therapeutics Inc. (Seattle, Wash.) debuted on Wednesday with $120 million in a series A round co-led by Arch Venture Partners and the Alaska Permanent Fund, through a partnership with Crestline Investors....
08:00 , Feb 18, 2013 |  BC Week In Review  |  Clinical News

All-In-One: Clinical trial started

Svelte began the international DIRECT II trial to compare its IDS vs. the Resolute Integrity drug-eluting stent in 159 patients. Medtronic Inc. (NYSE:MDT, Minneapolis, Minn.) markets Resolute Integrity, a zotarolimus-eluting coronary stent utilizing the BioLinx...
08:00 , Nov 14, 2011 |  BC Week In Review  |  Clinical News

All-In-One update

Svelte began the DIRECT trial to evaluate its All-In-One stent system in 30 patients. Svelte Medical Systems Inc. , New Providence, N.J.   Product: All-In-One   Business: Cardiovascular   Molecular target: NA   Description: Sirolimus-eluting...
07:00 , Oct 4, 2010 |  BioCentury  |  Finance

4Q Financial Markets Preview: Watershed moment

If biotech companies hit their milestones this quarter, the resulting stock upticks and opportunities to raise money could support both companies and investors for years. On the other hand, if things go wrong, generalists could...